UOC
BIOS

UBS O'Connor’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

UBS O'Connor’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-453,158
Closed -$4.91M – 667
2023
Q3 		$4.91M Hold
453,158
– – 0.09% 124
2023
Q2 		$4.83M Sell
453,158
-10,214
-2% -$107K 0.1% 117
2023
Q1 		$4.84M Hold
463,372
– – 0.11% 127
2022
Q4 		$4.76M Sell
463,372
-4,535
-1% -$46K 0.09% 180
2022
Q3 		$4.7M Sell
467,907
-46,842
-9% -$469K 0.05% 289
2022
Q2 		$5.17M Hold
514,749
– – 0.05% 253
2022
Q1 		$5.09M Buy
+514,749
New +$5.08M 0.06% 283

UBS O'Connor's BIOS Position: Q4 2023 in Review

UBS O'Connor sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 453,158 shares — an estimated $4.91M sold.

UBS O'Connor first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $5.17M in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

  • UBS O'Connor reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 453,158 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $4.91M.
  • UBS O'Connor first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
  • UBS O'Connor's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $5.17M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.